These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

270 related items for PubMed ID: 18790608

  • 21. A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context.
    Ball P, Mandell L, Patou G, Dankner W, Tillotson G.
    Int J Antimicrob Agents; 2004 May; 23(5):421-9. PubMed ID: 15120718
    [Abstract] [Full Text] [Related]

  • 22. [Role of oral fluoroquinolones in patients with respiratory diseases].
    Ishida T.
    Kekkaku; 2003 Oct; 78(10):653-9. PubMed ID: 14621574
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Comparison of in vitro activities of tigecycline with other antimicrobial agents against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in two university hospitals in Istanbul, Turkey.
    Gonullu N, Catal F, Kucukbasmaci O, Ozdemir S, Torun MM, Berkiten R.
    Chemotherapy; 2009 Oct; 55(3):161-7. PubMed ID: 19390189
    [Abstract] [Full Text] [Related]

  • 25. Pharmacokinetic-pharmacodynamic modelling of antibacterial activity of cefpodoxime and cefixime in in vitro kinetic models.
    Liu P, Rand KH, Obermann B, Derendorf H.
    Int J Antimicrob Agents; 2005 Feb; 25(2):120-9. PubMed ID: 15664481
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Prulifloxacin: a new antibacterial fluoroquinolone.
    Prats G, Rossi V, Salvatori E, Mirelis B.
    Expert Rev Anti Infect Ther; 2006 Feb; 4(1):27-41. PubMed ID: 16441207
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. [Clinical contribution of the newer fluoroquinolones in acute bacterial exacerbation of chronic bronchitis].
    Niederman MS.
    Medicina (B Aires); 1999 Feb; 59 Suppl 1():23-30. PubMed ID: 10436551
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Sitafloxacin: in bacterial infections.
    Keating GM.
    Drugs; 2011 Apr 16; 71(6):731-44. PubMed ID: 21504249
    [Abstract] [Full Text] [Related]

  • 36. Optimal dose finding of garenoxacin based on population pharmacokinetics/pharmacodynamics and Monte Carlo simulation.
    Tanigawara Y, Nozawa K, Tsuda H.
    Eur J Clin Pharmacol; 2012 Jan 16; 68(1):39-53. PubMed ID: 21796376
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Microbiology and antimicrobial management of sinusitis.
    Brook I.
    J Laryngol Otol; 2005 Apr 16; 119(4):251-8. PubMed ID: 15949076
    [Abstract] [Full Text] [Related]

  • 40. Novel biaryl oxazolidinones: in vitro and in vivo activities with pharmacokinetics in an animal model.
    Barman TK, Pandya M, Mathur T, Bhadauriya T, Rao M, Khan S, Singhal S, Bhateja P, Sood R, Malhotra S, Das B, Paliwal J, Bhatnagar PK, Upadhyay DJ.
    Int J Antimicrob Agents; 2009 Mar 16; 33(3):280-4. PubMed ID: 19091517
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.